Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04855006
Other study ID # HH-Dyscover-2021
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 1, 2021
Est. completion date March 24, 2023

Study information

Verified date March 2023
Source Copenhagen University Hospital, Hvidovre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Vaginal dysbiosis is a common condition among women. Vaginal dysbiosis covers imbalances in the vaginal flora, caused by the composition of microbes, bacteria, viruses and fungi. Dysbiosis occurs in about 16% of all women in Denmark. A large proportion of women who have vaginal dysbiosis do not experience any symptoms. However, vaginal dysbiosis can present challenges in several contexts, including a higher tendency for bacterial infections in the female genitals, lower chances of pregnancy in women undergoing fertility treatment, just as it can predispose to premature birth. This project is aimed at women aged 18-40, who wants to participate in a study to investigate whether, by transplanting vaginal secretion from one woman with a normal vaginal bacterial flora to another woman with an imbalance in the vaginal bacterial flora (called vaginal dysbiosis), can establish a normal vaginal bacterial flora in the recipient of the transplant. The study will also explore weather genetic, immunological, hormonal, metabolic, health behaviors and clinical factors have significance on whether a normal vaginal flora is achieved after transplantation.


Description:

06.12.2021 - Amendment to protocol. A subgroup of 24 women included in the main study as recipients, were asked to participate in delivery of menstrual blood (2-3 times) and peripheral blood (2-3 times). This to analyse immunological cells via flowcytometry in women with vaginal dysbiosis and if there is a change after engraftment of the VMT product. 17.05.2022 - Amendment to protocol. Those/if any women who did not convert their vaginal microbiome is asked to participate in a substudy with 2 arms. Local pretreatment with antiseptic and saline water before VMT and local pretreatment with saline water before VMT. 26.09.2022 - Amendment to protocol. Study arm with only pretreatment of antiseptic was added to the amendment from the 17.05.2022.


Recruitment information / eligibility

Status Completed
Enrollment 302
Est. completion date March 24, 2023
Est. primary completion date January 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: Donor: - a woman between 18 and 40 years old; - generally healthy and do not suffer from an immunological or other chronic diseases; - have regular menstruation or do not menstruate due to birth control pills, gestagen pills (mini-pills), etonogestrel birth control implant or hormone IUD; - not or do not have a desire to become pregnant within the next year; - willing to be asked personal questions in the form of medical history, current use of medication, sexuality and sexual behavior; - willing to refrain from vaginal intercourse unless a condom is used during certain periods of participation; and - can read and understand information material in Danish or English. - Accept not to use any intravaginal products such as tampons, menstrual cup, sex toys, vaginal cleaning products, spermicide products and vaginal lubrication. Recipient: - a woman between 18 and 40 years old; - generally healthy and do not suffer from an immunological or other chronic diseases; - have regular menstruation or do not menstruate due to birth control pills, gestagen pills (mini-pills), etonogestrel birth control implant or hormone IUD; - not or do not have a desire to become pregnant within the next year; - willing to be asked personal questions in the form of medical history, current use of medication, sexuality and sexual behavior; - willing to refrain from vaginal intercourse unless a condom is used during certain periods of participation; and - can read and understand information material in Danish or English. - Accept not to use any intravaginal products such as tampons, menstrual cup, sex toys, vaginal cleaning products, spermicide products and vaginal lubrication. Exclusion Criteria: Donor: - Being pregnant - Any medical history of bacterial vaginosis, Trichomoniasis, Syphilis, HPV, herpes, intraabdominal infections, recurrent urine infections or Mycoplasma infections. - Positive test result of HIV, Hepatitis A, B and C, Chlamydia, Gonorré, Mycoplasma, Trichonomas, HPV, herpes simplex and Streptococcus A, B, C and G. - Currently pregnant or lactating. - Any history of Gonorré and/or Chlamydia during the last year. - Have been travelling or have had a sexual partner who has been travelling to countries with Ebola and/or Zika virus within the last year. - Any other medical history, current use of medicine, travels or behavior which from a doctor's perspective is considered not suitable for being a donor. - Hysterectomized - Have participated in other medical studies within the last 30 days - Removal of IUD, cervical cryotheraphy or cervical laser-treatment up until 3 months before screening. - Any condition requiring the use of antibiotics in the investigation period - Usage of long-acting hormonal therapy within the last 3 months prior to screening. - Any social, medical or psychological condition including any history of drug and alcohol abuse, where it is evaluated that the participant cannot adhere to the protocol - Unsatisfying examination and screening results evaluated by a doctor - Any sexual habits, history or sexual partner, where the behavior can lead to an increased risk of sexual infections. - Usage of medicine, recently vaccinated or other behavior which is considered to be a hinder for participation. Recipient: - Being pregnant - Planning to become pregnant within the next 6 months - Lactating - Being less than 8 weeks post partum - Known positive HIV/AIDS infection or other immune diseases - Positive test result of HIV, Hepatitis A, B and C, Chlamydia, Gonorré, Mycoplasma, Trichonomas, positive urine hCG and HPV. - Have participated in other medical studies within the last 30 days - Removal of IUD, cervical cryotheraphy or cervical laser-treatment up until 3 months before screening. - Any condition requiring the use of antibiotics in the investigation period - Usage of long-acting hormonal therapy within the last 3 months prior to screening. - Any social, medical or psychological condition including any history of drug and alcohol abuse, where it is evaluated that the participant cannot adhere to the protocol - Unsatisfying examination and screening results evaluated by a doctor

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Vaginal Microbiome Transplant
Vaginal Microbiome Transplant is given at least once and up to three times. The transplant is admitted with a syringe
Vaginal Microbiome Transplant Placebo
Vaginal Microbiome Transplant Placebo is given at least once and up to three times. The transplant Placebo is admitted with a syringe
Other:
No intervention
Donors have no intervention. This group deliver the transplant to arm 'Vaginal Microbiome Transplant'.

Locations

Country Name City State
Denmark Hvidovre Hospital Copenhagen Hvidovre

Sponsors (1)

Lead Sponsor Collaborator
Copenhagen University Hospital, Hvidovre

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Engraftment of transplanted vaginal microbiome The number of patients who shifts from having a vaginal dysbiosis to not having a vaginal dysbiosis 7 days after the transplant - up to 3 transplants. 63 days from transplantation
Secondary Engraftment of transplanted vaginal microbiome after one transplantation The number of patients who shifts from having a vaginal dysbiosis to not having a vaginal dysbiosis 7 days after the transplant. 7 days from transplantation
Secondary Changes in the recipients vaginal bacterial composition Changes in the recipients vaginal bacterial composition after and during the intervention time 63 days from transplantation
See also
  Status Clinical Trial Phase
Completed NCT00838357 - A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). Phase 3
Terminated NCT00778856 - Hand Transplantation for the Reconstruction of Below the Elbow Amputations N/A
Active, not recruiting NCT00166842 - Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets Phase 4
Recruiting NCT04257747 - Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI N/A
Completed NCT02560909 - Adjuvanted Influenza Vaccine in Stem Cell Transplant Phase 4
Active, not recruiting NCT01687192 - Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy. Phase 2
Completed NCT00951977 - Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study N/A
Completed NCT00384202 - A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients Phase 3
Completed NCT00384137 - A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients Phase 3
Completed NCT00235664 - Prospective Study of Drug Resistant Pathogens Among Liver, Intestinal and Multivisceral Transplant Recipients N/A
Completed NCT03533049 - mHealth Family Self-Management N/A
Completed NCT02826213 - Comparison of Two Techniques of Renal Pre-transplant Infusion on the Evolution of Renal Function in the Recipient
Completed NCT00170170 - Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation N/A
Recruiting NCT06367244 - Transplant Wellness Program N/A
Recruiting NCT06166186 - Effect of Intraoperative Music on Inflammatory Response in Donor Hepatectomy N/A
Recruiting NCT00493194 - Fibrosis in Renal Allografts Phase 4
Completed NCT00297310 - Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation Phase 4
Completed NCT01019811 - Innervated Sensory Cross-Finger Flap N/A
Completed NCT04376775 - Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation
Active, not recruiting NCT00166816 - The Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant Patients Phase 4